Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone Versus Depo Medrol in Lumbar Epidurals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic low back pain of radicular origin of \> 4 weeks but \< 6 months~2. Failure of conservative therapy to include physical therapy and pharmacotherapy~3. Patient is at least 21 years of age~4. Patient is willing to be blinded to treatment until after the 12 week post injection visit.~5. Patient is willing and able to review and sign the study informed consent form.~Exclusion Criteria:~1. Patient has a mental or physical condition that would invalidate evaluation results.~2. Patient has had prior lumbar surgery at any level.~3. Patient is scheduled to have more than one level of steroid injection.~4. Patient is pregnant~5. Patient has systemic infection at the proposed injection site~6. Patient has osteopenia osteoporosis, or osteomalacia~7. Patient has a disease of bone metabolism~8. Patient has history of renal insufficiency or kidney disease of any kind~9. Patient is undergoing chemotherapy or radiation treatment~10. Patient is currently involved in a study of another product for similar purpose~11. Patient requires post op management with NSAIDS~12. Patient has know allergy to corticosteroids, contrast dye or anesthetics~13. Patient is unable to speak/read English~14. Patient is a prisoner

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): Subjects randomized to receive dexamethasone, will undergo epidural using this medication, however the physician and subject will be blinded
- methylprednisolone acetate (Type: ACTIVE_COMPARATOR): Subjects randomized to receive methylprednisolone acetate, will undergo epidural using this medication, however the physician and subject will be blinded

Based on this trial design, predict the completion outcome and termination type (if applicable).